The clinical impact of growth differentiation factor-15 in heart disease: A 2019 update.
Level 5 - mechanism / opinion, no new human data
Narrative review summarizing mechanisms and clinical applications without systematic review methodology
PubMed 31663791 · doi:10.1080/10408363.2019.1678565
What was done
This narrative review summarizes the biological origins, cellular secretion pathways, and clinical applications of growth differentiation factor-15 (GDF-15) in heart disease. The authors review cellular sources (cardiac myocytes, macrophages, endothelial cells, vascular smooth muscle cells, adipocytes), triggers of secretion (oxidative stress, ischemia, mechanical stretch, angiotensin II, proinflammatory cytokines), and its role as a prognostic marker across conditions such as hypertrophic and dilated cardiomyopathy and heart failure.
What was found
The abstract provides no numerical data, hazard ratios, or statistical cutoffs. It qualitatively describes GDF-15 induction during myocardial stretch, volume overload, and ischemia, and notes that it provides prognostic information when paired with conventional cardiovascular biomarkers such as N-terminal pro B-type natriuretic peptide (NT-proBNP) and high-sensitivity troponin T (hs-TnT).
Why it matters
It provides a consolidated overview of GDF-15 as a multi-pathway biomarker reflecting oxidative, inflammatory, and mechanical stress in heart disease, supporting its potential use in multi-marker risk assessment panels.
Limits
As a narrative review, it lacks a formal systematic search protocol, quality assessment of included studies, or quantitative meta-analysis. The abstract provides no specific patient numbers, cut-off values, or effect sizes for clinical decision-making.
Cited by
- supports GDF15 is significantly elevated in heart failure and dilated cardiomyopathy and serves as a diagnostic/prognostic biomarker in cardiology.